...for Meniere disease: SP-1005 (an oral formulation of ebselen) from Sound Pharmaceuticals Inc., latanoprost (JB004) from Synphora AB...
...in a Phase IIb trial. The candidate is now in Phase III testing. JB004 targets PGF2ɑ. Synphora...
...F2 ɑ receptor Danielle Golovin Otividex, dexamethasone (OTO-104) ORB-202, betamethasone Intranasal betahistine (AM-125) latanoprost (JB004) SPI-1005 (ebselen) Otonomy Inc. Adare Pharma Solutions Auris Medical Holding Ltd. Synphora AB Sound...

...compl Auris Medical AG AM-101 Small molecule NMDA receptor antagonist Acute tinnitus Ph IIb compl Synphora AB...

...study under a 2006 deal (see BioCentury, Oct. 16, 2006). Biovitrum AB (SSE:BVT), Stockholm, Sweden Synphora AB...

...BVT will provide Synphora with up to SEK5 million ($670,000) to help fund an ongoing Phase...
...ongoing Phase I trial of Synphora's JB991 for psoriasis and a potential Phase II trial. Synphora...
...which BVT will have an option to acquire the product. Biovitrum AB (SSE:BVT), Stockholm, Sweden Synphora AB...